The dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ) [17] has been shown to enhance the radiosensitivity of SQ20B laryngeal and FaDu hypopharyngeal cancer cells, overexpressing epidermal growth factor receptor (EGFR) [18]. This evidence concerns the gene EGFR and hypopharynx cancer.